WallStSmart

Teva Pharma Industries Ltd ADR (TEVA)vsViatris Inc (VTRS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Teva Pharma Industries Ltd ADR generates 19% more annual revenue ($17.35B vs $14.56B). TEVA leads profitability with a 9.0% profit margin vs -2.0%. VTRS appears more attractively valued with a PEG of 0.14. TEVA earns a higher WallStSmart Score of 66/100 (B-).

TEVA

Strong Buy

66

out of 100

Grade: B-

Growth: 6.0Profit: 7.0Value: 6.3Quality: 4.0
Piotroski: 6/9Altman Z: 0.28

VTRS

Buy

50

out of 100

Grade: C-

Growth: 3.3Profit: 3.5Value: 6.7Quality: 5.0
Piotroski: 4/9Altman Z: 0.55

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

TEVA2 strengths · Avg: 9.0/10
EPS GrowthGrowth
72.2%10/10

Earnings expanding 72.2% YoY

PEG RatioValuation
0.858/10

Growing faster than its price suggests

VTRS2 strengths · Avg: 10.0/10
PEG RatioValuation
0.1410/10

Growing faster than its price suggests

Price/BookValuation
1.2x10/10

Reasonable price relative to book value

Areas to Watch

TEVA4 concerns · Avg: 3.0/10
P/E RatioValuation
25.8x4/10

Moderate valuation

Revenue GrowthGrowth
2.3%4/10

2.3% revenue growth

Free Cash FlowQuality
$-208.00M2/10

Negative free cash flow — burning cash

Altman Z-ScoreHealth
0.282/10

Distress zone — elevated risk

VTRS4 concerns · Avg: 1.8/10
Return on EquityProfitability
-2.0%2/10

ROE of -2.0% — below average capital efficiency

EPS GrowthGrowth
-70.6%2/10

Earnings declined 70.6%

Altman Z-ScoreHealth
0.552/10

Distress zone — elevated risk

Profit MarginProfitability
-2.0%1/10

Currently unprofitable

Comparative Analysis Report

WallStSmart Research

Bull Case : TEVA

The strongest argument for TEVA centers on EPS Growth, PEG Ratio. PEG of 0.85 suggests the stock is reasonably priced for its growth.

Bull Case : VTRS

The strongest argument for VTRS centers on PEG Ratio, Price/Book. PEG of 0.14 suggests the stock is reasonably priced for its growth.

Bear Case : TEVA

The primary concerns for TEVA are P/E Ratio, Revenue Growth, Free Cash Flow. Debt-to-equity of 2.05 is elevated, increasing financial risk.

Bear Case : VTRS

The primary concerns for VTRS are Return on Equity, EPS Growth, Altman Z-Score.

Key Dynamics to Monitor

TEVA profiles as a value stock while VTRS is a turnaround play — different risk/reward profiles.

VTRS carries more volatility with a beta of 0.90 — expect wider price swings.

VTRS is growing revenue faster at 8.1% — sustainability is the question.

VTRS generates stronger free cash flow (348M), providing more financial flexibility.

Bottom Line

TEVA scores higher overall (66/100 vs 50/100). Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Teva Pharma Industries Ltd ADR

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic drugs, specialty drugs, and biopharmaceuticals in North America, Europe, and internationally. The company is headquartered in Petach Tikva, Israel.

Viatris Inc

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Viatris Inc. is an American global healthcare company headquartered in Canonsburg, Pennsylvania.

Visit Website →

Want to dig deeper into these stocks?